170 results match your criteria toxin btxa


Observations on the Efficacy of Two Methods for the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy.

Biomed Res Int 2021 18;2021:9514279. Epub 2021 Mar 18.

Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China.

Objective: To observe the clinical efficacy of periocular injection of triamcinolone acetonide (TA) and subpalpebral injection of botulinum toxin type A (BTXA) for the treatment of thyroid-associated ophthalmopathy (TAO) with mild unilateral upper eyelid retraction.

Method: This was a prospective randomized controlled study. A total of 68 cases of stable thyroid-associated ophthalmopathy with mild upper eyelid retraction were collected at Hankou Aier Eye Hospital from Jan. Read More

View Article and Full-Text PDF

Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study.

Orphanet J Rare Dis 2021 Feb 18;16(1):93. Epub 2021 Feb 18.

Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France.

Background: Patients with Hailey-Hailey and Darier diseases present with disabling inflammatory lesions located in large skin folds, which are often exacerbated or induced by sweating. Quality of life is highly impaired because of pain and recurrent skin infections. An improvement in skin lesions after botulinum toxin A injections has previously been reported in some patients but no prospective interventional studies are available. Read More

View Article and Full-Text PDF
February 2021

Botulinum Toxin Injection with Conjunctival Microincision for the Treatment of Acute Acquired Comitant Esotropia and Its Effectiveness.

J Ophthalmol 2020 31;2020:1702695. Epub 2020 Dec 31.

Department of Ophthalmology, Hebei Provincial Key Laboratory of Ophthalmology, Hebei Eye Hospital, Xingtai, Hebei Province 054000, China.

Purpose: To report on an improved botulinum toxin injection with conjunctival microincision for beginners, and to determine the effectiveness of botulinum toxin A (BTXA) in the treatment of patients with acute acquired comitant esotropia (AACE).

Methods: Medical records of 29 AACE patients were retrospectively analyzed. BTXA was injected into the unilateral or bilateral medial rectus muscle with conjunctival microincision without electromyographic guidance. Read More

View Article and Full-Text PDF
December 2020

Evaluation of Intradermal Injection of Botulinum Toxin A for Facial Lifting.

J Clin Aesthet Dermatol 2020 Dec 1;13(12):22-26. Epub 2020 Dec 1.

Dr. Atwa is a Professor of Dermatology, Venereology, and Andrology and member of the Faculty of Medicine at Zagazig University in Ash Sharqia Governorate, Egypt.

Intradermal botolinum toxin A (BTXA) is an advanced technique that emerged in response to the increased demand for noninvasive facial lifting and skin rejuvenation. We sought to evaluate the safety and efficacy of intradermal injections of BTXA for facial lifting. Twenty-five female patients with mild symmetrical facial skin laxity were enrolled in this study. Read More

View Article and Full-Text PDF
December 2020

Functional acute acquired comitant esotropia: clinical characteristics and efficacy of single Botulinum toxin type A injection.

BMC Ophthalmol 2020 Nov 25;20(1):464. Epub 2020 Nov 25.

Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiefang Road 88#, Hangzhou, 310009, Zhejiang Province, China.

Background: To examine the clinical features of acute acquired comitant esotropia (AACE) and to evaluate the clinical effectiveness of a single injection of botulinum toxin type A (BTXA) on binocular visual function (BVF).

Methods: This retrospective, observational case series study enrolled patients with AACE examined from October 2018-May 2019. BTXA was injected into the both medial rectus muscles. Read More

View Article and Full-Text PDF
November 2020

Morphea-like lesions after botulinum toxin A injections.

JAAD Case Rep 2020 Nov 31;6(11):1185-1187. Epub 2020 Aug 31.

Dermatology, Cambridge, Massachusetts.

View Article and Full-Text PDF
November 2020

Effects of botulinum toxin A on endometriosis‑associated pain and its related mechanism.

Mol Med Rep 2020 Nov 10;22(5):4351-4359. Epub 2020 Sep 10.

Department of Anesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090, P.R. China.

Endometriosis (EMS) is a common disease in women aged 25‑45 years, and pain is the main clinical symptom. The primary clinical treatment is surgical excision and drug therapy targeting the ectopic lesions, but these have not been very effective. Botulinum neurotoxin serotype A (BTX‑A) has been reported to be useful in the treatment of pain in a variety of diseases. Read More

View Article and Full-Text PDF
November 2020

Aberrantly expressed lncRNAs and mRNAs after botulinum toxin type A inhibiting salivary secretion.

Oral Dis 2020 Sep 6. Epub 2020 Sep 6.

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing, China.

Objective: In this study, we sought to determine the expression profiles of long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) and construct functional networks to analyze their potential roles following botulinum toxin type A (BTXA)-mediated inhibition of salivary secretion.

Methods: The submandibular gland of rats in the BTXA and control groups was injected with BTXA and saline, respectively. Microarray analysis was used to identify the differentially expressed lncRNAs and mRNAs. Read More

View Article and Full-Text PDF
September 2020

Botulinum toxin complications in registered and off-label aesthetic indications.

J Cosmet Dermatol 2020 Oct 28;19(10):2484-2490. Epub 2020 Aug 28.

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark.

Botulinum toxin A (BTXA) is one of the most popular nonsurgical cosmetic procedures worldwide. Overall, this procedure is associated with favorable complications profile. Nevertheless, any medical intervention carries inherent risks. Read More

View Article and Full-Text PDF
October 2020

Over 25 Years of Pediatric Botulinum Toxin Treatments: What Have We Learned from Injection Techniques, Doses, Dilutions, and Recovery of Repeated Injections?

Authors:
Heli Sätilä

Toxins (Basel) 2020 07 6;12(7). Epub 2020 Jul 6.

Department of Neuropediatrics, Päijät-Häme Central Hospital, Lahti, Finland, Keskussairaalankatu 7, 15850 Lahti, Finland.

Botulinum toxin type A (BTXA) has been used for over 25 years in the management of pediatric lower and upper limb hypertonia, with the first reports in 1993. The most common indication is the injection of the triceps surae muscle for the correction of spastic equinus gait in children with cerebral palsy. The upper limb injection goals include improvements in function, better positioning of the arm, and facilitating the ease of care. Read More

View Article and Full-Text PDF

Effects of Botulinum Toxin Type A on Microvessels in Hypertrophic Scar Models on Rabbit Ears.

Biomed Res Int 2020 16;2020:2170750. Epub 2020 Jun 16.

Department of Oculoplastic Surgery, Hankou Aier Eye Hospital, Wuhan, China.

Background: Although Botulinum Toxin Type A (BTXA) has been applied to scar prevention and treatment, the mechanisms still require further exploration.

Objective: To investigate the effects of BTXA on microvessels in the hypertrophic scar models on rabbit ears.

Methods: Eight big-eared New Zealand rabbits (males or females) were selected to establish scar models. Read More

View Article and Full-Text PDF

Efficacy and Safety of Botulinum Toxin Type A in Preventing Postoperative Scars and Improving the Cosmetic Appearance of Scars: A Systematic Review and Meta-Analysis.

J Cutan Med Surg 2020 Nov/Dec;24(6):608-618. Epub 2020 Jul 1.

36639 Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Background: Scars with poor cosmesis that develop after wound healing may affect normal life.

Objective: To assess the efficacy and safety of botulinum toxin type A (BTXA) in preventing postoperative hypertrophic scars or keloids.

Methods: A systematic review was performed by searching the PubMed, Cochrane Library, and EMBASE databases from their inception date up to February 2020 for randomized controlled trials (RCTs) evaluating the efficacy of BTXA in preventing hypertrophic scars or keloids. Read More

View Article and Full-Text PDF

Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders.

J Voice 2020 May 26. Epub 2020 May 26.

Department of Otolaryngology - Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia.

Laryngeal botulinum toxin injection is an important treatment modality for spasmodic dysphonia and other laryngeal disorders. We sought to compare usage patterns of laryngeal botulinum toxin injections for voice disorders and to identify and quantify inefficiencies and barriers in providing this treatment. A 26 item survey was written and approved for distribution by the American Academy of Otolaryngology-Head and Neck Surgery and the National Spasmodic Dysphonia Association. Read More

View Article and Full-Text PDF

Botulinum toxin type A for the treatment of dyssynergic defaecation in adults: a systematic review.

Colorectal Dis 2020 May 13. Epub 2020 May 13.

National Bowel Research Centre and GI Physiology Unit (Colorectal Services), Centre of Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, UK.

Aim: Dyssynergic defaecation (DD) is characterized by inappropriate coordination of the pelvic floor muscles during defaecation, resulting in impaired stool expulsion. The mainstay of treatment is biofeedback and alternative therapies are limited in those who do not respond. This systematic review evaluated botulinum toxin type A injection (BTXA) as a treatment option for dyssynergia. Read More

View Article and Full-Text PDF

The Positive Effects of a Calorie-Restricting High-Protein Diet Combined with Intragastric Botulinum Toxin Type A Application Among Morbidly Obese Patients: A Prospective, Observational Analysis of Eighty-Seven Grade 2 Obese Patients.

Obes Surg 2020 Sep;30(9):3472-3479

Department of General Surgery, Faculty of Medicine, Istanbul Okan University, Istanbul, Turkey.

Purpose: Many studies evaluating the effect of intragastric botulinum toxin type A injection (IG-BTxA) for the treatment of obesity have been published. However, none of these studies combined this procedure with a calorie-restricting high-protein diet. Herein, we aimed to evaluate the effects of IG-BTxA application combined with a calorie-restricting high-protein diet. Read More

View Article and Full-Text PDF
September 2020

ABOUT FACE: Navigating Neuromodulators and Injection Techniques for Optimal Results

J Drugs Dermatol 2020 Apr;19(4):s5-s15

Interest in the cosmetic use of neuromodulators for facial rejuvenation is increasing among physicians, other practitioners, and patients alike, and an expanding array of formulations and reported applications might be helping to drive this trend. Safety, efficacy, and a high level of patient satisfaction can be achieved with all the available botulinum neurotoxin type A (BTXA) products. With any of the formulations, optimal results require knowledge of the individual product’s unique properties and dosing, along with an understanding of the patient’s goals, relevant anatomy, and proper injection technique. Read More

View Article and Full-Text PDF

BTXA regulates the epithelial-mesenchymal transition and autophagy of keloid fibroblasts via modulating miR-1587/miR-2392 targeted ZEB2.

Biosci Rep 2019 10;39(10)

Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, Shenzhen 518110, Guangdong, China.

Keloids are very resistant to treatment in dermatology and plastic surgical practice. The present study aimed to explore the underlying mechanism of botulinum toxin A (BTXA) treated human skin keloid fibroblasts (HSFBs) proving some new insights into keloids treatment. Expression of miR-1587 and miR-2392 were significantly down-regulated in keloid tissues and HSFBs, while the ZEB2 was a target of both and up-regulated in keloid tissues and HSFBs compared with the normal controls. Read More

View Article and Full-Text PDF
October 2019

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation.

Int Neurourol J 2019 Sep 30;23(3):226-233. Epub 2019 Sep 30.

Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.

Purpose: Intradetrusor onabotulinum toxin A (BTXA) and sacral neuromodulation (SNM) are effective third-line therapies for overactive bladder (OAB). We aimed to measure the outcomes of BTXA for treatment of OAB refractory to initial SNM and identify patient characteristics associated with these outcomes.

Methods: This retrospective cohort study included patients who failed to respond to initial SNM treatment for OAB and subsequently received BTXA at a single provider's clinic between January 2013 and December 2016. Read More

View Article and Full-Text PDF
September 2019

Appropriate Timing of Early Postoperative Botulinum Toxin Type A Injection for Thyroidectomy Scar Management: A Split-Scar Study.

Plast Reconstr Surg 2019 10;144(4):659e-668e

From the Department of Dermatology and the Division of Breast and Endocrine Surgery, College of Medicine, Hallym University.

Background: Botulinum toxin type A (BTxA) injection is effective for surgical scar prevention. Although some studies have aimed to confirm the efficacy of BTxA injection at different time points, none has been conducted to determine the most appropriate timing of injection for scar management. The authors predicted that the injection of BTxA at different times during the wound healing process would cause differing scar quality improvement and clarify unknown molecular mechanisms. Read More

View Article and Full-Text PDF
October 2019

The Safety and efficacy of botulinum toxin type A injection for postoperative scar prevention: A systematic review and meta-analysis.

J Cosmet Dermatol 2020 Apr 12;19(4):799-808. Epub 2019 Sep 12.

Department of Plastic and Reconstructive Surgery, Peking University People 's Hospital, Beijing, China.

Background: Active prevention and treatment of scars are particularly important. Several studies have used botulinum toxin type A(BTXA) to prevent postoperative scarring. The aim of this systematic review and meta-analysis was to systematically evaluate the efficacy and safety of BTXA in preventing and treating postoperative scars. Read More

View Article and Full-Text PDF

Botulinum toxin type A interrupts autophagic flux of submandibular gland.

Biosci Rep 2019 07 23;39(7). Epub 2019 Jul 23.

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, 22# Zhongguancun South Avenue, Haidian District, Beijing 100081, China

Botulinum toxin type A (BTXA) is a neurotoxic protein produced by Our previous studies demonstrated that BTXA inhibits the secretory function of submandibular gland (SMG) and changes its structure. Several studies reported that SMG damage and repair often occur with autophagy in the rat. However, no studies reported whether secretory inhibition and structural changes of SMG after BTXA injection is related with autophagy. Read More

View Article and Full-Text PDF

Botulinum toxin type A prevents the phenotypic transformation of fibroblasts induced by TGF‑β1 via the PTEN/PI3K/Akt signaling pathway.

Int J Mol Med 2019 Aug 31;44(2):661-671. Epub 2019 May 31.

Department of Dermatology and Plastic Surgery, Beijing Chaoyang Hospital, Jingxi Campus, Capital Medical University, Beijing 100043, P.R. China.

Hypertrophic scar (HS) is a common type of dermatosis. Botulinum toxin type A (BTXA) can exert an anti‑HS effect; however, the regulatory mechanisms underlying this effect remain unclear. Thus, the aim of this study was to examine the effects of BTXA on phosphatase and tensin homolog deleted on chromosome ten (PTEN) expression and the fibroblast phenotypic transformation induced by transforming growth factor (TGF)‑β1, which is an important regulatory factor involved in the process of HS. Read More

View Article and Full-Text PDF

Efficacy and Safety of Botulinum Toxin Type A for Limb Spasticity after Stroke: A Meta-Analysis of Randomized Controlled Trials.

Biomed Res Int 2019 7;2019:8329306. Epub 2019 Apr 7.

Department of Rehabilitation Medicine, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570102, China.

Background: Inconsistent data have been reported for the effectiveness of intramuscular botulinum toxin type A (BTXA) in patients with limb spasticity after stroke. This meta-analysis of available randomized controlled trials (RCTs) aimed to determine the efficacy and safety of BTXA in adult patients with upper and lower limb spasticity after stroke.

Methods: An electronic search was performed to select eligible RCTs in PubMed, Embase, and the Cochrane library through December 2018. Read More

View Article and Full-Text PDF

Botulinum Toxin Type A Injection After Failure of Augmentation Enterocystoplasty Performed for Neurogenic Detrusor Overactivity: Preliminary Results of a Salvage Strategy. The ENTEROTOX Study.

Urology 2019 Jul 26;129:43-47. Epub 2019 Mar 26.

Department of Urology & Kidney Transplantation, Aix Marseille Univesity, La Conception University Hospital, Marseille, France. Electronic address:

Objective: To evaluate the clinical efficacy, urodynamic effect and safety of Botulinum Toxin A (BTXA) injections after failure of augmentation enterocystoplasty (AE) performed for neurogenic detrusor overactivity.

Patients And Methods: We performed a multicenter retrospective study that included patients who had AE and at least one injection of BTXA after AE in 15 GENULF (French Speaking Neuro-Urology Study Group) centers. Clinical and urodynamic data were collected from medical files according to a standardized questionnaire and colligated in an anonymous database. Read More

View Article and Full-Text PDF

Effectiveness and Safety of Botulinum Toxin Type A Injection for Scar Prevention: A Systematic Review and Meta-analysis.

Aesthetic Plast Surg 2019 10 21;43(5):1241-1249. Epub 2019 Mar 21.

Department of Plastic Surgery, The First Affiliated Hospital, Anhui Medical University, 218 JiXi Road, Hefei, 230022, Anhui Province, China.

Background: The role of active scar prevention in postoperative scar management is important. Botulinum toxin type A (BTXA) has been shown to improve postoperative scars in the past decades. The aim of this systematic review and meta-analysis was to evaluate the effectiveness and safety of BTXA injection for scar prevention. Read More

View Article and Full-Text PDF
October 2019

Botulinum Toxin Type A Attenuates Apoptosis in Human Dermal Microvascular Endothelial Cells Exposed to an In Vitro Model of Ischemia/Reperfusion Injury.

Authors:
Y Shi H Lin J Cao C Cui

Transplant Proc 2019 Apr 7;51(3):966-971. Epub 2019 Jan 7.

Department of Aesthetic Plastic Surgery and Laser Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Background: Botulinum toxin type A (BTXA) has been reported to increase survival of critically ischemic skin flaps; however, the effect of BTXA in human dermal microvascular endothelial cells (HDMECs) remains to be investigated. This study aimed to investigate the protective effect of BTXA in HDMECs exposed to an in vitro model of ischemia/reperfusion injury.

Methods: HDMECs were isolated from human upper eyelid tissue and were randomly divided into 3 groups: 1. Read More

View Article and Full-Text PDF

Neuromuscular dysfunction, independent of gait dysfunction, modulates trabecular bone homeostasis in mice.

J Musculoskelet Neuronal Interact 2019 03;19(1):79-93

Department of Orthopaedics and Sports Medicine, University of Washington.

Objectives: To clarify the effects of neuromuscular dysfunction on hindlimb loading, muscle atrophy, and bone homeostasis.

Methods: We quantified changes to hindlimb loading, muscle atrophy, and bone morphology following either Botulinum toxin A (BTxA) induced muscle paralysis or peripheral nerve injury (PNI) in mice; two in vivo models that we anticipated would differently alter gait and mechanical loading patterns due to their distinct effects on neuromuscular signaling. To confirm the expected behavioral effects of PNI, we assessed mechanical allodynia of the ipsilateral hindlimb using von Frey testing and activity (distance traveled and speed) was monitored in both groups using open field testing. Read More

View Article and Full-Text PDF

Botulinum toxin type A induces protective autophagy in human dermal microvascular endothelial cells exposed to an model of ischemia/reperfusion injury.

Exp Ther Med 2018 Dec 17;16(6):4379-4386. Epub 2018 Sep 17.

Department of Plastic and Reconstructive Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China.

Botulinum toxin type A (BTXA) has been reported to increase the survival of ischemic skin flaps; however, the exact mechanism underlying this effect remains unclear and needs to be further established. The present study aimed to elucidate whether autophagy caused by BTXA functions as a protection mechanism and to identify the mechanisms of its regulation by BTXA in human dermal microvascular endothelial cells (HDMECs) subjected to hypoxia/reoxygenation (H/R)-induced injury. HDMECs were harvested from the upper eyelid tissues of female blepharoplasty patients. Read More

View Article and Full-Text PDF
December 2018

The efficacy of superior rectus recession with simultaneous inferior oblique disinsertion on superior oblique palsy with superior rectus contracture.

Strabismus 2019 03 7;27(1):16-23. Epub 2018 Dec 7.

a Department of Ophthalmology , Adnan Menderes University Medical School , Aydin , Turkey.

Purpose: The information about superior rectus (SR) recession in cases with SR contracture coexisting with superior oblique palsy (SOP) is very limited in previous literature. The aim of this study is to evaluate the effect of SR recession, as a combined procedure with inferior oblique (IO) disinsertion, in long-standing SOP with secondary SR contracture.

Methods: The medical records of the 145 patients operated for SOP were retrospectively reviewed and 15 patients who underwent SR recession met the inclusion criteria. Read More

View Article and Full-Text PDF